United States - English - NLM (National Library of Medicine)

bayer healthcare llc animal health division - pradofloxacin (unii: 6o0t5e048i) (pradofloxacin - unii:6o0t5e048i) - pradofloxacin 25 mg in 1 ml - veraflox is indicated for the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of pasteurella multocida, streptococcus canis, staphylococcus aureus, staphylococcus felis, and staphylococcus pseudintermedius. do not use in dogs. pradofloxacin has been shown to cause bone marrow suppression in dogs. dogs may be particularly sensitive to this effect, potentially resulting in severe thrombocytopenia and neutropenia. quinolone-class drugs have been shown to cause arthropathy in immature animals of most species tested, the dog being particularly sensitive to this side effect. pradofloxacin is contraindicated in cats with a known hypersensitivity to quinolones.

United States - English - NLM (National Library of Medicine)

bayer healthcare, llc animal health division - imidacloprid (unii: 3bn7m937v8) (imidacloprid - unii:3bn7m937v8) - imidacloprid 7.5 mg - advantus™ kills adult fleas and is indicated for the treatment of flea infestations on dogs and puppies 10 weeks of age and older and weighing 4 pounds or greater.

United States - English - NLM (National Library of Medicine)

bayer healthcare llc animal health division - imidacloprid (unii: 3bn7m937v8) (imidacloprid - unii:3bn7m937v8), moxidectin (unii: ngu5h31yo9) (moxidectin - unii:ngu5h31yo9) - imidacloprid 100 mg in 1 ml - advantage multi for cats is indicated for the prevention of heartworm disease caused by dirofilaria immitis . advantage multi for cats kills adult fleas (ctenocephalides felis ) and is indicated for the treatment of flea infestations. advantage multi for cats is also indicated for the treatment and control of ear mite (otodectes cynotis ) infestations and the following intestinal parasites: intestinal parasite intestinal stage adult immature adult fourth stage larvae hookworm species ancylostoma tubaeforme x x x roundworm species toxocara cati x x for ferrets: advantage multi for cats is indicated for the prevention of heartworm disease in ferrets caused by dirofilaria immitis . advantage multi for cats kills adult fleas (ctenocephalides felis ) and is indicated for the treatment of flea infestations on ferrets.

United States - English - NLM (National Library of Medicine)

bayer healthcare llc animal health division - praziquantel (unii: 6490c9u457) (praziquantel - unii:6490c9u457), emodepside (unii: yz647y5gc9) (emodepside - unii:yz647y5gc9) - praziquantel 30 mg in 0.35 ml - profender topical solution is indicated for the treatment and control of hookworm infections caused by ancylostoma tubaeforme (adults, immature adults, and fourth stage larvae), roundworm infections caused by toxocara cati (adults and fourth stage larvae), and tapeworm infections caused by dipylidium caninum (adults) and taenia taeniaeformis (adults) in cats.

United States - English - NLM (National Library of Medicine)

bayer healthcare, llc animal health division - florfenicol (unii: 9j97307y1h) (florfenicol - unii:9j97307y1h), terbinafine (unii: g7riw8s0xp) (terbinafine - unii:g7riw8s0xp), mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - claro® is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (malassezia pachydermatis ) and bacteria (staphylococcus pseudintermedius ). do not use in dogs with known tympanic membrane perforation (see precautions ). claro® is contraindicated in dogs with known or suspected hypersensitivity to florfenicol, terbinafine hydrochloride, or mometasone furoate.

United States - English - NLM (National Library of Medicine)

bayer healthcare, llc animal health division - moxidectin (unii: ngu5h31yo9) (moxidectin - unii:ngu5h31yo9) - coraxis is indicated for the prevention of heartworm disease caused by dirofilaria immitis. coraxis is also indicated for the treatment and control of the following intestinal parasites: intestinal parasite intestinal stage adult immature adult fourth stage larvae hookworm species ancylostoma caninum x x x uncinaria stenocephala x x x roundworm species toxocara canis x x toxascaris leonina x whipworm trichuris vulpis x do not administer this product orally. (see warnings.) do not use this product (containing 2.5% moxidectin) on cats.

United States - English - NLM (National Library of Medicine)

bayer healthcare, llc animal health division - praziquantel (unii: 6490c9u457) (praziquantel - unii:6490c9u457), pyrantel pamoate (unii: 81bk194z5m) (pyrantel - unii:4qih0n49e7), febantel (unii: s75c401os1) (febantel - unii:s75c401os1) - praziquantel 22.7 mg - quad dewormer (praziquantel/pyrantel pamoate/febantel) chewable tablets for dogs will remove the common tapeworms, dipylidium caninum and taenia pisiformis , remove common hookworms, ancylostoma caninum and uncinaria stenocephala , remove common roundworms, toxocara canis and toxascaris leonina , and remove whipworms, trichuris vulpis in dogs.

United States - English - NLM (National Library of Medicine)

bayer healthcare llc animal health division - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn), butyl alcohol (unii: 8pj61p6ts3) (butyl alcohol - unii:8pj61p6ts3) - enrofloxacin 22.7 mg in 1 ml - baytril® (brand of enrofloxacin) injectable solution is indicated for the management of diseases in dogs associated with bacteria susceptible to enrofloxacin. efficacy confirmation: clinical efficacy was established in dermal infections (wounds and abscesses) associated with susceptible strains of escherichia coli , klebsiella pneumoniae , proteus mirabilis , and staphylococcus intermedius ; respiratory infections (pneumonia, tonsillitis, rhinitis) associated with susceptible strains of escherichia coli and staphylococcus aureus ; and urinary cystitis associated with susceptible strains of escherichia coli , proteus mirabilis , and staphylococcus aureus . enrofloxacin is contraindicated in dogs known to be hypersensitive to quinolones. based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in lar

United States - English - NLM (National Library of Medicine)

bayer healthcare llc animal health division - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 22.7 mg - baytril® (brand of enrofloxacin) antibacterial tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. baytril antibacterial tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.

United States - English - NLM (National Library of Medicine)

bayer healthcare llc animal health division - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 22.7 mg - baytril® (brand of enrofloxacin)taste tabs® antibacterial tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. baytril antibacterial tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or gia